Landos Biopharma to Present at the 38th Annual J.P. Morgan Healthcare Conference
BLACKSBURG, Va., Jan. 9, 2020– Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that Dr. Josep Bassaganya-Riera, Chairman, President, and Chief Executive Officer, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference. Dr. Bassaganya-Riera’s presentation will take place on Monday, January 13, 2020, at 8:30 a.m. PST in the Elizabethan C/D ballroom of the Westin St. Francis in San Francisco. A live audio webcast of the presentation will be accessible through the Company’s News & Events section at www.landosbiopharma.com.
Dr. Bassaganya-Riera will provide an update on the clinical advancement of Landos’ lead program, BT-11, a novel, orally-administered, gut-restricted, first-in-class therapeutic that targets LANCL2 in clinical development for ulcerative colitis (UC) and Crohn’s disease (CD), plus additional pipeline drug candidates that target new immunometabolic pathways. Topline results for the BT-11 Phase 2 randomized, placebo-controlled, double-blind, parallel-group, multicenter induction and maintenance 195 UC patient study are expected in the second half of 2020.
“I am delighted that Landos has been invited to present at this premier industry event. The J.P. Morgan Healthcare conference represents a great opportunity to provide further visibility for our ongoing drug development efforts centered around new immunometabolic pathways and designed to address the unmet clinical needs for patients with widespread and debilitating autoimmune diseases,” said Dr. Josep Bassaganya-Riera.
In 2019, Landos announced the successful completion of its $60 million Series B financing round co-led by RTW Investments and Perceptive Advisors (Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund), and joined by additional new investors including Osage University Partners and entities affiliated with Paul Manning. Proceeds support global Phase 2 testing of lead product BT-11 for UC and CD, and advancement of additional pipeline candidates such as initiating clinical testing of NX-13, an oral therapeutic targeting NLRX1.
The NIMML Institute is a 501 (c) (3) non-profit public charity foundation focused on a transdisciplinary, team-science approach to precision medicine at the interface of immunology, inflammation, and metabolism. The NIMML Institute team has led numerous large-scale transdisciplinary projects and is dedicated to solving important societal problems by combining the expertise of immunologists, computational biologists, toxicologists, modelers, translational researchers, and molecular biologists. The Institute is headquartered in Blacksburg, VA. For more information, please visit www.nimml.org or contact firstname.lastname@example.org.